drugset / Trial / NCT00718237

Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)

NCT00718237

Phase 3 Completed 762 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of the study is to evaluate whether V260 is effective and well tolerated in Japanese healthy infants.

Timeline

Start
2008-08
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotarix Vaccine Oral